Thank you.

BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.

AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.

The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.

BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.

Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.

BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.

BenevolentAI and Drugs for Neglected Disease initiative (DNDi) enter a joint research project to use AI to accelerate drug discovery research in dengue, a climate-sensitive neglected disease.

RECOVERY trial data show Eli Lilly-owned baricitinib reduces death in patients hospitalised with COVID-19, further validating BenevolentAI’s initial AI-derived hypothesis.

BenevolentAI and the Helix Group — led by Prof. Russ Altman — partner on research into more effective methods to extract knowledge from biological information.

BenevolentAI and Stanford University review progress in their AI research partnership, which looks at the role of ​​co​​ntext in information extraction.